Header Logo

Connection

Khurshida Begum to Humans

This is a "connection" page, showing publications Khurshida Begum has written about Humans.
Connection Strength

0.400
  1. A quantitative PCR to detect non-toxigenic Clostridioides difficile. Microbiol Spectr. 2025 Jan 07; 13(1):e0160824.
    View in: PubMed
    Score: 0.094
  2. Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
    View in: PubMed
    Score: 0.024
  3. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
    View in: PubMed
    Score: 0.022
  4. Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
    View in: PubMed
    Score: 0.022
  5. The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0156322.
    View in: PubMed
    Score: 0.021
  6. Fusobacteria behaving badly: Masquerading strains of strictly anaerobic Escherichiacoli misidentified due to the deletion of the hemB gene. Anaerobe. 2023 Feb; 79:102682.
    View in: PubMed
    Score: 0.021
  7. Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clin Infect Dis. 2022 09 30; 75(7):1164-1170.
    View in: PubMed
    Score: 0.020
  8. Isolation and characterisation of carbapenem-resistant Pseudomonas aeruginosa from hospital environments in tertiary care hospitals in Dhaka, Bangladesh. J Glob Antimicrob Resist. 2022 09; 30:31-37.
    View in: PubMed
    Score: 0.020
  9. Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings. Anaerobe. 2022 Jun; 75:102543.
    View in: PubMed
    Score: 0.019
  10. Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe. 2021 Dec; 72:102440.
    View in: PubMed
    Score: 0.019
  11. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
    View in: PubMed
    Score: 0.018
  12. A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. J Antimicrob Chemother. 2020 12 01; 75(12):3635-3643.
    View in: PubMed
    Score: 0.018
  13. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
    View in: PubMed
    Score: 0.018
  14. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020; 9(1):341-347.
    View in: PubMed
    Score: 0.017
  15. Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe. 2020 Feb; 61:102081.
    View in: PubMed
    Score: 0.016
  16. Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe. 2019 Apr; 56:88-90.
    View in: PubMed
    Score: 0.016
  17. Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.